1. EGPA

3. This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US.

4. Introduction What Is EGPA?

5. Diagnostic Criteria, Classification, and Definition of EGPA

6. Incorporating EGPA Definition and Criteria Into Practice

7. Clinical Presentation and Diagnosis of EGPA

8. The Three "Classic" Phases of EGPA

9. Diagnosing EGPA in Patients Taking Corticosteroids

10. Overcoming Challenges of Diagnosing EGPA

11. EGPA Is an ANCA-Associated Vasculitis

12. Significance of ANCA in EGPA

13. Eosinophils Play a Major Role in the Pathophysiology of EGPA

14. Management and Treatment of EGPA

15. Targeting IL-5 for the Treatment of EGPA

16. IL-5 Targeted Therapy for EGPA Mepolizumab

17. Steroid Reduction With Mepolizumab

18. Emerging Therapies

19. Multidisciplinary Team Approach

20. Longitudinal Assessment of EGPA

21. Concluding Remarks

22. Abbreviations